Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136


Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition.

El Zaoui I, Bucher M, Rimoldi D, Nicolas M, Kaya G, Pescini Gobert R, Bedoni N, Schalenbourg A, Sakina E, Zografos L, Leyvraz S, Riggi N, Rivolta C, Moulin AP.

Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2764-2772. doi: 10.1167/iovs.18-26508.


Paracrine Activin-A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion.

Donovan P, Dubey OA, Kallioinen S, Rogers KW, Muehlethaler K, Müller P, Rimoldi D, Constam DB.

J Invest Dermatol. 2017 Dec;137(12):2578-2587. doi: 10.1016/j.jid.2017.07.845. Epub 2017 Aug 26.


Broad and Conserved Immune Regulation by Genetically Heterogeneous Melanoma Cells.

Neubert NJ, Tillé L, Barras D, Soneson C, Baumgaertner P, Rimoldi D, Gfeller D, Delorenzi M, Fuertes Marraco SA, Speiser DE.

Cancer Res. 2017 Apr 1;77(7):1623-1636. doi: 10.1158/0008-5472.CAN-16-2680. Epub 2017 Jan 19.


Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals JP, Rimoldi D, Gnjatic S, Abed Maillard S, Marcos Mondéjar P, Protti MP, Romano E, Michielin O, Romero P, Speiser DE, Jandus C.

Oncoimmunology. 2016 Sep 9;5(10):e1216290. eCollection 2016.


Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing.

Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, Raynaud F, Zografos L, Schalenbourg A, Speiser D, Nicolas M, Vallat L, Klein R, Leyvraz S, Ciriello G, Riggi N, Moulin AP, Rivolta C.

Am J Hum Genet. 2016 Nov 3;99(5):1190-1198. doi: 10.1016/j.ajhg.2016.09.008. Epub 2016 Oct 13.


A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells.

Neubert NJ, Soneson C, Barras D, Baumgaertner P, Rimoldi D, Delorenzi M, Fuertes Marraco SA, Speiser DE.

Front Immunol. 2016 Aug 30;7:326. doi: 10.3389/fimmu.2016.00326. eCollection 2016.


Fast Diagnostics of BRAF Mutations in Biopsies from Malignant Melanoma.

Huber F, Lang HP, Glatz K, Rimoldi D, Meyer E, Gerber C.

Nano Lett. 2016 Sep 14;16(9):5373-7. doi: 10.1021/acs.nanolett.6b01513. Epub 2016 Aug 9.


Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements.

Homulle HA, Powolny F, Stegehuis PL, Dijkstra J, Li DU, Homicsko K, Rimoldi D, Muehlethaler K, Prior JO, Sinisi R, Dubikovskaya E, Charbon E, Bruschini C.

Biomed Opt Express. 2016 Apr 11;7(5):1797-814. doi: 10.1364/BOE.7.001797. eCollection 2016 May 1.


Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.

Yao J, Caballero OL, Huang Y, Lin C, Rimoldi D, Behren A, Cebon JS, Hung MC, Weinstein JN, Strausberg RL, Zhao Q.

Cancer Immunol Res. 2016 Jun;4(6):552-61. doi: 10.1158/2326-6066.CIR-15-0255. Epub 2016 Apr 4.


UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation.

Rivolta C, Royer-Bertrand B, Rimoldi D, Schalenbourg A, Zografos L, Leyvraz S, Moulin A.

J Hum Genet. 2016 Apr;61(4):361-2. doi: 10.1038/jhg.2015.152. Epub 2015 Dec 10. No abstract available.


Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.

Clin Cancer Res. 2016 Mar 15;22(6):1330-40. doi: 10.1158/1078-0432.CCR-15-1212. Epub 2015 Oct 23.


Nanosensors for cancer detection.

Huber F, Lang HP, Zhang J, Rimoldi D, Gerber C.

Swiss Med Wkly. 2015 Feb 9;145:w14092. doi: 10.4414/smw.2015.14092. eCollection 2015. Review.


Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.

Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, Speiser D, Peters S, Rimoldi D, Michielin O.

Clin Cancer Res. 2013 Oct 15;19(20):5749-57. doi: 10.1158/1078-0432.CCR-13-0661. Epub 2013 Aug 15.


Increased plasticity of the stiffness of melanoma cells correlates with their acquisition of metastatic properties.

Weder G, Hendriks-Balk MC, Smajda R, Rimoldi D, Liley M, Heinzelmann H, Meister A, Mariotti A.

Nanomedicine. 2014 Jan;10(1):141-8. doi: 10.1016/j.nano.2013.07.007. Epub 2013 Jul 24.


[Congenital hypothyroidism secondary to thyroid hypoplasia detected in adulthood].

Monti P, Roveto S, Rajuan S, Gazzi C, Rimoldi D.

Medicina (B Aires). 2013;73(2):145-7. Spanish.


Direct detection of a BRAF mutation in total RNA from melanoma cells using cantilever arrays.

Huber F, Lang HP, Backmann N, Rimoldi D, Gerber Ch.

Nat Nanotechnol. 2013 Feb;8(2):125-9. doi: 10.1038/nnano.2012.263. Epub 2013 Feb 3.


Breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates MITF.

Anghel SI, Correa-Rocha R, Budinska E, Boligan KF, Abraham S, Colombetti S, Fontao L, Mariotti A, Rimoldi D, Ghanem GE, Fisher DE, Lévy F, Delorenzi M, Piguet V.

Pigment Cell Melanoma Res. 2012 Jul;25(4):482-7. doi: 10.1111/j.1755-148X.2012.01018.x. Erratum in: Pigment Cell Melanoma Res. 2012 Nov;25(6):834. Correa-Rochal, Rafael [corrected to Correa-Rocha, Rafael]; Boliganl, Kayluz F [corrected to Boligan, Kayluz F].


Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals JP, Baumgaertner P, Christiansen-Jucht C, Bouzourene H, Rimoldi D, Pircher H, Rufer N, Matter M, Michielin O, Speiser DE.

PLoS One. 2012;7(2):e30852. doi: 10.1371/journal.pone.0030852. Epub 2012 Feb 8.


Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE.

Nat Genet. 2011 Dec 25;44(2):133-9. doi: 10.1038/ng.1026.


Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma.

Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, Quadroni M, Waridel P, Gaillard M, Pidoux M, Rapin B, Rivolta C, Xenarios I, Simpson AJ, Antonarakis SE, Beckmann JS, Jongeneel CV, Iseli C, Stevenson BJ.

PLoS One. 2011 Apr 8;6(4):e18369. doi: 10.1371/journal.pone.0018369.


TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer.

Salaun B, Zitvogel L, Asselin-Paturel C, Morel Y, Chemin K, Dubois C, Massacrier C, Conforti R, Chenard MP, Sabourin JC, Goubar A, Lebecque S, Pierres M, Rimoldi D, Romero P, Andre F.

Cancer Res. 2011 Mar 1;71(5):1607-14. doi: 10.1158/0008-5472.CAN-10-3490. Epub 2011 Feb 22.


Frequent MAGE mutations in human melanoma.

Caballero OL, Zhao Q, Rimoldi D, Stevenson BJ, Svobodová S, Devalle S, Röhrig UF, Pagotto A, Michielin O, Speiser D, Wolchok JD, Liu C, Pejovic T, Odunsi K, Brasseur F, Van den Eynde BJ, Old LJ, Lu X, Cebon J, Strausberg RL, Simpson AJ.

PLoS One. 2010 Sep 16;5(9). pii: e12773. doi: 10.1371/journal.pone.0012773. Erratum in: PLoS One. 2010;5(11). doi: 10.1371/annotation/3ee2788f-0c44-429f-85c3-d626c9fedc21.


Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma.

Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, Liénard D, Monnier P, Romero P, Bron L, Rimoldi D.

Int J Cancer. 2011 Jun 1;128(11):2625-34. doi: 10.1002/ijc.25607. Epub 2010 Oct 8.


Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients.

Laurent J, Speiser DE, Appay V, Touvrey C, Vicari M, Papaioannou A, Canellini G, Rimoldi D, Rufer N, Romero P, Leyvraz S, Voelter V.

J Immunother. 2010 Sep;33(7):723-34. doi: 10.1097/CJI.0b013e3181ea7e6e.


The E3 ubiquitin ligase Itch regulates sorting nexin 9 through an unconventional substrate recognition domain.

Baumann C, Lindholm CK, Rimoldi D, Lévy F.

FEBS J. 2010 Jul;277(13):2803-14. doi: 10.1111/j.1742-4658.2010.07698.x. Epub 2010 May 20.


BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE.

J Clin Invest. 2010 Jan;120(1):157-67. doi: 10.1172/JCI40070. Epub 2009 Dec 28.


Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant.

Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE.

J Immunother. 2009 Oct;32(8):875-83. doi: 10.1097/CJI.0b013e3181b56ad9.


Identification of tumor-associated antigens by large-scale analysis of genes expressed in human colorectal cancer.

Alves PM, Lévy N, Stevenson BJ, Bouzourene H, Theiler G, Bricard G, Viatte S, Ayyoub M, Vuilleumier H, Givel JC, Rimoldi D, Speiser DE, Jongeneel CV, Romero PJ, Lévy F.

Cancer Immun. 2008 Jun 27;8:11.


Infrequent promoter methylation of the MGMT gene in liver metastases from uveal melanoma.

Voelter V, Diserens AC, Moulin A, Nagel G, Yan P, Migliavacca E, Rimoldi D, Hamou MF, Kaina B, Leyvraz S, Hegi ME.

Int J Cancer. 2008 Sep 1;123(5):1215-8. doi: 10.1002/ijc.23632.


c-Cbl expression levels regulate the functional responses of human central and effector memory CD4 T cells.

Brembilla NC, Weber J, Rimoldi D, Pradervand S, Schütz F, Pantaleo G, Rüegg C, Quadroni M, Harshman K, Doucey MA.

Blood. 2008 Aug 1;112(3):652-60. doi: 10.1182/blood-2008-01-134486. Epub 2008 May 27.


An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.

Voelter V, Pica A, Laurent J, Rimoldi D, Bouzourene H, Sajadi A, Matter M, Romero P, Rufer N, Speiser DE.

Cancer Immun. 2008 Mar 27;8:6. No abstract available.


Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanoma.

Willi JP, Matter M, Buchegger F, Antonescu C, Guggisberg D, Cerottini JP, Krischer J, Braun R, Marie Kurt A, Roche B, Lemoine R, Rimoldi D, Lejeune FJ, Liénard D, Bischof Delaloye A.

Nuklearmedizin. 2007;46(6):244-51.


Toll-like receptor 3 expressed by melanoma cells as a target for therapy?

Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4565-74.


Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.

Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; European Organization for Research and Treatment of Cancer Melanoma Group.

Clin Cancer Res. 2007 Jul 1;13(13):3825-30.


[Seric 21-hydroxilase antibodies in patients with anti-microsomal fraction antibodies. Autoimmune polyendocrine syndrome].

Botta S, Roveto S, Rimoldi D.

Medicina (B Aires). 2007;67(2):143-6. Spanish.


New approaches in metastatic melanoma: biological and molecular targeted therapies.

Lejeune FJ, Rimoldi D, Speiser D.

Expert Rev Anticancer Ther. 2007 May;7(5):701-13. Review.


Potential target antigens for immunotherapy in human pancreatic cancer.

Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R, Niethammer AG, Beckhove P, Buchler MW, Z'graggen K.

Cancer Lett. 2007 Jul 18;252(2):290-8. Epub 2007 Feb 22.


Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.

Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P.

J Immunol. 2006 Nov 15;177(10):6769-79.


New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.

J Immunol. 2006 Aug 1;177(3):1670-8.


A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.

Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Liénard D, Cerottini JC, Romero P, Rufer N.

J Immunol. 2006 Jul 15;177(2):1338-48.


Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells.

Batard P, Peterson DA, Devêvre E, Guillaume P, Cerottini JC, Rimoldi D, Speiser DE, Winther L, Romero P.

J Immunol Methods. 2006 Mar 20;310(1-2):136-48. Epub 2006 Feb 17.


Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.

Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.

Cancer Res. 2006 Feb 15;66(4):1912-6.


Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.

van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, Meijer CJ, Kummer JA.

Clin Cancer Res. 2005 Sep 1;11(17):6400-7.


CD4+ T cell responses to SSX-4 in melanoma patients.

Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D.

J Immunol. 2005 Apr 15;174(8):5092-9.


Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation.

Lévy F, Muehlethaler K, Salvi S, Peitrequin AL, Lindholm CK, Cerottini JC, Rimoldi D.

Mol Biol Cell. 2005 Apr;16(4):1777-87. Epub 2005 Feb 9.


Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P.

J Clin Invest. 2005 Mar;115(3):739-46.


Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.

Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE.

J Immunol. 2005 Feb 1;174(3):1709-16.


Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas.

Lahav R, Suvà ML, Rimoldi D, Patterson PH, Stamenkovic I.

Cancer Res. 2004 Dec 15;64(24):8945-53.


Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.

Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D.

Clin Immunol. 2005 Jan;114(1):70-8.


Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2004 May 19;4:4.

Supplemental Content

Loading ...
Support Center